Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk-Adapted Stanford V-C With Radiotherapy for Clinical Stage I and IIA Favorable Hodgkin's Disease: The G5 Study

NCT00026208 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT00026208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00026208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk-Adapted Stanford V-C With Radiotherapy for Clinical Stage I and IIA Favorable Hodgkin's Disease: The G5 Study
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2001
Completion date
February 13, 2017
Enrollment
76 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin disease, lymphoma, lymphoma, hodgkin disease, lymphoma: hodgkin